JBIONasdaqPharmaceutical PreparationsFiscal year ends December 31
Jade Biosciences, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026
$13.83+0.36 (+2.67%)
Close on Oct 19, 2026
- Market cap
- $844.33M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
100.0%
73M of 64M shares
Institutional holders
154
52 new, 16 sold out
Net institutional buying
25M
In Q2 2026
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Fairmount Funds Management LLC | 7,249,356 | 19.99% | 13D (active) | Apr 28, 2025 |
| JANUS HENDERSON GROUP Ltd. | 6,273,262 | 10.60% | 13G (passive) amendment | Jun 30, 2026 |
| Bong Y. Koh | 5,145,330 | 8.30% | 13G (passive) amendment | Jun 30, 2026 |
| Abigail P. Johnson | 4,735,951 | 14.70% | 13G (passive) | May 30, 2025 |
| Bellevue Group AG | 3,341,103 | 6.80% | 13G (passive) | Dec 16, 2025 |
| Venrock Healthcare Capital Partners III, L.P. | 3,220,369 | 9.90% | 13G (passive) | Apr 28, 2025 |
| Peter Kolchinsky | 3,214,969 | 7.00% | 13G (passive) | Oct 8, 2025 |
| Senai Asefaw, M.D. | 3,106,793 | 5.10% | 13G (passive) | Jul 10, 2026 |
| Janus Henderson Group PLC | 3,105,669 | 6.30% | 13G (passive) amendment | Mar 31, 2026 |
| Bellevue Asset Management AG | 3,057,996 | 5.00% | 13G (passive) amendment | Jun 30, 2026 |
| David Kroin | 2,784,648 | 8.64% | 13G (passive) | Apr 28, 2025 |
| James N. Topper | 1,772,116 | 5.50% | 13G (passive) | Apr 28, 2025 |
| Peter Evan Harwin | 14,069,494 | 19.99% | 13D (active) amendment | Jun 5, 2026 |
| Tomas Kiselak | 10,353,875 | 19.99% | 13D (active) amendment | Oct 6, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of JBIO | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| FMR LLC | 9,126,877 | 14.35% | $202.80M | +2,041,454 | 0.01% |
| Jupiter Topco LLC | 6,273,262 | 9.86% | $139.37M | New | 0.06% |
| Fairmount Funds Management LLC | 4,553,494 | 7.16% | $101.18M | – | 6.69% |
| Ra Capital Management, L.P. | 3,671,083 | 5.77% | $81.57M | – | 0.71% |
| VR Adviser, LLC | 3,220,364 | 5.06% | $71.56M | – | 2.17% |
| Bellevue Group AG | 3,057,996 | 4.81% | $67.95M | −443,506 | 1.43% |
| Paradigm Biocapital Advisors LP | 2,857,405 | 4.49% | $63.49M | New | 1.19% |
| BlackRock, Inc. | 2,801,451 | 4.40% | $62.25M | +487,502 | 0.00% |
| Franklin Resources Inc | 2,792,080 | 4.39% | $62.04M | New | 0.01% |
| State Street Corp | 2,335,285 | 3.67% | $51.89M | +1,679,595 | 0.00% |
| Vanguard Capital Management LLC | 2,244,773 | 3.53% | $49.88M | +448,121 | 0.00% |
| Adage Capital Partners Gp, L.L.C. | 1,910,812 | 3.00% | $42.46M | New | 0.06% |
| Polar Capital Holdings Plc | 1,846,982 | 2.90% | $41.04M | New | 0.10% |
| Avidity Partners Management LP | 1,700,708 | 2.67% | $37.79M | −1,100,708 | 6.05% |
| Remedium Capital Partners, LLC | 1,577,750 | 2.48% | $35.06M | – | 7.76% |
| Soleus Capital Management, L.P. | 1,550,690 | 2.44% | $34.46M | +753,946 | 1.19% |
| JPMorgan Chase & Co | 1,475,079 | 2.32% | $32.61M | +1,459,216 | 0.00% |
| Baker Bros. Advisors LP | 1,230,426 | 1.93% | $27.34M | −410,711 | 0.14% |
| Logos Global Management LP | 1,125,000 | 1.77% | $25.00M | +725,000 | 1.08% |
| Versant Venture Management, LLC | 991,783 | 1.56% | $22.04M | −534,037 | 13.55% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 154 | 73M | 100.0% | 52 / 60 | 26 / 16 | 31M | 7M |
| Q1 2026 | 120 | 51M | 80.8% | 29 / 39 | 33 / 13 | 10M | 4M |
| Q4 2025 | 105 | 47M | 74.0% | 33 / 43 | 15 / 6 | 20M | 5M |
| Q3 2025 | 78 | 32M | 49.7% | 8 / 23 | 22 / 3 | 1M | 1M |
| Q2 2025 | 73 | 32M | 49.6% | 73 / 0 | 0 / 0 | 32M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of JBIO | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1,699,343 | 2.67% | $37.76M | 0.00% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 1,533,573 | 2.41% | $34.08M | 0.32% | Jun 30, 2026 |
| Franklin Small Cap Value Fund | 1,412,559 | 2.22% | $27.90M | 0.65% | Jul 31, 2026 |
| Fidelity Growth Company Fund | 1,009,957 | 1.59% | $21.25M | 0.02% | May 31, 2026 |
| Fidelity Stock Selector Small Cap Fund | 908,146 | 1.43% | $17.94M | 0.24% | Jul 31, 2026 |
| iShares Russell 2000 ETF | 852,070 | 1.34% | $18.93M | 0.02% | Jun 30, 2026 |
| Fidelity Small Cap Growth Fund | 779,915 | 1.23% | $15.40M | 0.18% | Jul 31, 2026 |
| Janus Henderson Global Life Sciences Fund | 716,799 | 1.13% | $15.93M | 0.27% | Jun 30, 2026 |
| Fidelity Advisor Biotechnology Fund | 698,671 | 1.10% | $13.80M | 0.63% | Jul 31, 2026 |
| JPMorgan Small Cap Growth Fund | 677,766 | 1.07% | $15.06M | 0.58% | Jun 30, 2026 |
| Select Health Care Portfolio | 640,000 | 1.01% | $13.47M | 0.23% | May 31, 2026 |
| Fidelity Series Small Cap Opportunities Fund | 589,200 | 0.93% | $11.64M | 0.25% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 484,964 | 0.76% | $10.78M | 0.01% | Jun 30, 2026 |
| Franklin Biotechnology Discovery Fund | 479,949 | 0.75% | $9.48M | 0.82% | Jul 31, 2026 |
| Franklin Small Cap Growth Fund | 432,709 | 0.68% | $8.55M | 0.35% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Tom Frohlich | Chief Executive Officer, Director | 86,331 | 0.14% | Feb 13, 2026 |
| Elizabeth Balta | See Remarks | 28,125 | 0.04% | Feb 13, 2026 |
| Bradford D. Dahms | Chief Financial Officer | 37,813 | 0.06% | Feb 13, 2026 |
| Andrew James King | See Remarks | 386,113 | 0.61% | Feb 13, 2026 |
| Hetal Kocinsky | Chief Medical Officer | – | – | May 1, 2025 |
| Jonathan Quick | See Remarks | – | – | May 1, 2025 |
| Mark Eisner | Director | – | – | Jun 26, 2026 |
| Eric Dobmeier | Director | – | – | Jun 11, 2026 |
| Erin Lavelle | Director | – | – | Jun 11, 2026 |
| Healthcare Co-Invest IV L.P. Fairmount | Director, 10% owner | – | – | Jun 11, 2026 |
| Healthcare Fund II L.P. Fairmount | Director, 10% owner | 4,553,494 | 7.16% | Jun 11, 2026 |
| Tomas Kiselak | Director, 10% owner | – | – | Jun 11, 2026 |
| Funds Management LLC Fairmount | Director, 10% owner | – | – | Jun 11, 2026 |
| Peter Evan Harwin | Director, 10% owner | – | – | Jun 11, 2026 |
| Lawrence Otto Klein | Director | 86,215 | 0.14% | Jun 11, 2026 |
| Christopher W. Cain | Director | – | – | Jun 11, 2026 |
| Ra Capital Management, L.P. | 10% owner | – | – | Apr 30, 2025 |
| Peter Kolchinsky | 10% owner | 1,287,858 | 2.03% | Apr 30, 2025 |
| Rajeev M. Shah | 10% owner | 7,893,678 | 12.41% | Apr 30, 2025 |
| Capital Healthcare Fund LP RA | 10% owner | – | – | Apr 30, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Bradford D. Dahms Chief Financial Officer | Feb 12, 2026 | Award | +37,813 | – | – | 37,813 |
| Tom Frohlich Chief Executive Officer, Director | Feb 12, 2026 | Award | +78,750 | – | – | 86,331 |
| Andrew James King See Remarks | Feb 12, 2026 | Award | +41,250 | – | – | 386,113 |
| Elizabeth Balta See Remarks | Feb 12, 2026 | Award | +28,125 | – | – | 28,125 |
| Healthcare Fund II L.P. Fairmount Director, 10% owner | Oct 6, 2025 | Award | +1,333,126 | $9.14 | $12.18M | 1,897,677 |
| Tom Frohlich Chief Executive Officer, Director | May 16, 2025 | Buy | +6,000 | $7.40 | $44.40K | 6,000 |
| Peter Kolchinsky 10% owner | Apr 28, 2025 | Other | +1,062,326 | – | – | 1,287,858 |
| Benjamin T. Dake SEE REMARKS | Aug 1, 2024 | Option exercise | +1,507 | $1.74 | $2.62K | 14,252 |
| Benjamin T. Dake SEE REMARKS | Jul 31, 2024 | Option exercise | +11,454 | $1.74 | $19.93K | 12,745 |
| Rajeev M. Shah Director, 10% owner | Jun 17, 2024 | Buy | +928,110 | $1.67 | $1.55M | 7,893,678 |
| George A. Eldridge SEE REMARKS | Jun 14, 2024 | Option exercise | +15,000 | $2.14 | $32.10K | 20,022 |
| George A. Eldridge SEE REMARKS | Jun 14, 2024 | Sale(10b5-1 plan) | −15,000 | $25.03 | $375.45K | 5,022 |
| Marinus Verwijs CHIEF TECHNICAL OFFICER | Jun 14, 2024 | Option exercise | +10,600 | $14.59 | $154.65K | 10,600 |
| Marinus Verwijs CHIEF TECHNICAL OFFICER | Jun 14, 2024 | Sale(10b5-1 plan) | −10,600 | $25.00 | $265.00K | 0 |
| Hunter Gillies CHIEF MEDICAL OFFICER | Jun 13, 2024 | Option exercise | +6,000 | $2.14 | $12.84K | 11,602 |
| Hunter Gillies CHIEF MEDICAL OFFICER | Jun 13, 2024 | Sale(10b5-1 plan) | −6,000 | $24.50 | $147.00K | 5,602 |
| Hunter Gillies CHIEF MEDICAL OFFICER | May 17, 2024 | Option exercise | +4,000 | $2.14 | $8.56K | 9,602 |
| Hunter Gillies CHIEF MEDICAL OFFICER | May 17, 2024 | Sale(10b5-1 plan) | −3,914 | $21.07 | $82.47K | 5,688 |
| Hunter Gillies CHIEF MEDICAL OFFICER | May 17, 2024 | Sale(10b5-1 plan) | −86 | $21.86 | $1.88K | 5,602 |
| Timothy P. Noyes CHIEF EXECUTIVE OFFICER, Director | May 16, 2024 | Sale(10b5-1 plan) | −8,707 | $21.52 | $187.37K | 1,293 |
| Timothy P. Noyes CHIEF EXECUTIVE OFFICER, Director | May 16, 2024 | Sale(10b5-1 plan) | −1,293 | $21.92 | $28.34K | 0 |
| Timothy P. Noyes CHIEF EXECUTIVE OFFICER, Director | May 16, 2024 | Option exercise | +10,000 | $2.14 | $21.40K | 10,000 |
| Marinus Verwijs CHIEF TECHNICAL OFFICER | May 2, 2024 | Sale | −1,981 | $21.02 | $41.64K | 0 |
| Timothy P. Noyes CHIEF EXECUTIVE OFFICER, Director | May 1, 2024 | Sale(10b5-1 plan) | −1,357 | $19.91 | $27.02K | 0 |
| Timothy P. Noyes CHIEF EXECUTIVE OFFICER, Director | May 1, 2024 | Sale(10b5-1 plan) | −965 | $20.87 | $20.14K | 0 |
| Timothy P. Noyes CHIEF EXECUTIVE OFFICER, Director | May 1, 2024 | Sale(10b5-1 plan) | −9,035 | $20.34 | $183.77K | 965 |
| Timothy P. Noyes CHIEF EXECUTIVE OFFICER, Director | May 1, 2024 | Option exercise | +10,000 | $2.14 | $21.40K | 10,000 |
| Hunter Gillies CHIEF MEDICAL OFFICER | Apr 17, 2024 | Sale(10b5-1 plan) | −3,689 | $22.30 | $82.26K | 3,562 |
| Hunter Gillies CHIEF MEDICAL OFFICER | Apr 17, 2024 | Option exercise | +4,000 | $1.74 | $6.96K | 7,251 |
| Hunter Gillies CHIEF MEDICAL OFFICER | Apr 17, 2024 | Sale(10b5-1 plan) | −311 | $23.33 | $7.26K | 3,251 |
| Benjamin T. Dake SEE REMARKS | Apr 17, 2024 | Option exercise | +6,853 | $2.14 | $14.67K | 8,144 |
| Benjamin T. Dake SEE REMARKS | Apr 17, 2024 | Sale(10b5-1 plan) | −338 | $23.17 | $7.83K | 1,359 |
| Benjamin T. Dake SEE REMARKS | Apr 17, 2024 | Sale(10b5-1 plan) | −68 | $23.97 | $1.63K | 1,291 |
| Benjamin T. Dake SEE REMARKS | Apr 17, 2024 | Sale(10b5-1 plan) | −6,447 | $22.32 | $143.90K | 1,697 |
| Timothy P. Noyes CHIEF EXECUTIVE OFFICER, Director | Apr 16, 2024 | Option exercise | +10,000 | $2.14 | $21.40K | 10,000 |
| Timothy P. Noyes CHIEF EXECUTIVE OFFICER, Director | Apr 16, 2024 | Sale(10b5-1 plan) | −4,491 | $24.40 | $109.58K | 5,509 |
| Timothy P. Noyes CHIEF EXECUTIVE OFFICER, Director | Apr 16, 2024 | Sale(10b5-1 plan) | −5,509 | $24.94 | $137.39K | 0 |
| George A. Eldridge SEE REMARKS | Apr 10, 2024 | Option exercise | +7,500 | $2.14 | $16.05K | 9,460 |
| George A. Eldridge SEE REMARKS | Apr 10, 2024 | Sale(10b5-1 plan) | −6,729 | $26.77 | $180.14K | 2,731 |
| George A. Eldridge SEE REMARKS | Apr 10, 2024 | Sale(10b5-1 plan) | −771 | $27.56 | $21.25K | 1,960 |
| David S. Grayzel Director | Apr 9, 2024 | Sale | −11,882 | $28.15 | $334.48K | 14,502 |
| Marinus Verwijs CHIEF TECHNICAL OFFICER | Apr 1, 2024 | Option exercise | +5,300 | $14.59 | $77.33K | 5,300 |
| Marinus Verwijs CHIEF TECHNICAL OFFICER | Apr 1, 2024 | Sale(10b5-1 plan) | −1,504 | $30.00 | $45.12K | 0 |
| Marinus Verwijs CHIEF TECHNICAL OFFICER | Apr 1, 2024 | Sale(10b5-1 plan) | −3,796 | $28.87 | $109.59K | 1,504 |
| Benjamin T. Dake SEE REMARKS | Apr 1, 2024 | Option exercise | +3,325 | $10.61 | $35.28K | 4,616 |
| Benjamin T. Dake SEE REMARKS | Apr 1, 2024 | Sale(10b5-1 plan) | −3,325 | $31.97 | $106.30K | 1,291 |
| Timothy P. Noyes CHIEF EXECUTIVE OFFICER, Director | Apr 1, 2024 | Sale(10b5-1 plan) | −1,647 | $29.90 | $49.25K | 3,851 |
| Timothy P. Noyes CHIEF EXECUTIVE OFFICER, Director | Apr 1, 2024 | Sale(10b5-1 plan) | −4,502 | $28.96 | $130.38K | 5,498 |
| Timothy P. Noyes CHIEF EXECUTIVE OFFICER, Director | Apr 1, 2024 | Option exercise | +10,000 | $2.14 | $21.40K | 10,000 |
| Timothy P. Noyes CHIEF EXECUTIVE OFFICER, Director | Apr 1, 2024 | Sale(10b5-1 plan) | −1,000 | $31.95 | $31.95K | 0 |
| Timothy P. Noyes CHIEF EXECUTIVE OFFICER, Director | Apr 1, 2024 | Sale(10b5-1 plan) | −2,851 | $31.02 | $88.44K | 1,000 |
| George A. Eldridge SEE REMARKS | Apr 1, 2024 | Sale(10b5-1 plan) | −12,495 | $31.23 | $390.22K | 1,960 |
| George A. Eldridge SEE REMARKS | Apr 1, 2024 | Option exercise | +12,495 | $2.14 | $26.74K | 14,455 |
| Hunter Gillies CHIEF MEDICAL OFFICER | Mar 28, 2024 | Option exercise | +9,000 | $2.14 | $19.26K | 12,251 |
| Hunter Gillies CHIEF MEDICAL OFFICER | Mar 28, 2024 | Sale(10b5-1 plan) | −9,000 | $29.50 | $265.50K | 3,251 |
| Benjamin T. Dake SEE REMARKS | Mar 27, 2024 | Sale(10b5-1 plan) | −11,068 | $27.97 | $309.57K | 1,291 |
| Benjamin T. Dake SEE REMARKS | Mar 27, 2024 | Option exercise | +11,068 | $10.61 | $117.43K | 12,359 |
| Benjamin T. Dake SEE REMARKS | Mar 25, 2024 | Sale(10b5-1 plan) | −3,432 | $28.01 | $96.13K | 1,291 |
| Benjamin T. Dake SEE REMARKS | Mar 25, 2024 | Option exercise | +3,432 | $10.61 | $36.41K | 4,723 |
| Marinus Verwijs CHIEF TECHNICAL OFFICER | Mar 19, 2024 | Sale(10b5-1 plan) | −2,764 | $26.46 | $73.14K | 0 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Atlas Venture Associates XII, L.P. Shareholder | Jun 25, 2025 | 235 | $2.46K | Jun 25, 2025 | Private Placement |
| Atlas Venture Fund XII, L.P. Shareholder | Jun 25, 2025 | 28,977 | $303.68K | Jun 25, 2025 | Private Placement |
| Atlas Venture Fund XII, L.P. Shareholder | Jun 24, 2025 | 16,132 | $159.22K | Jun 24, 2025 | Private Placement |
| Atlas Venture Associates XII, L.P. Shareholder | Jun 24, 2025 | 131 | $1.29K | Jun 24, 2025 | Private Placement |
| Atlas Venture Fund XII, L.P. Shareholder | May 6, 2025 | 5,883 | $67.65K | May 6, 2025 | Private Placement |
| Atlas Venture Associates XII, L.P. Shareholder | May 6, 2025 | 48 | $552 | May 6, 2025 | Private Placement |
| Verwijs Marinus Officer | Jun 14, 2024 | 10,600 | $265.00K | Jun 14, 2024 | Stock Option Exercise |
| C. Gillies Hunter Officer | Jun 13, 2024 | 6,000 | $147.00K | Jun 13, 2024 | Stock Option Exercise |
| C. Gillies Hunter Officer | May 17, 2024 | 4,000 | $84.33K | May 17, 2024 | Stock Option Exercise |
| Noyes Timothy Officer, Director | May 16, 2024 | 10,000 | $215.76K | May 16, 2024 | Stock Option Exercise |
| Marinus Verwijs Officer | May 2, 2024 | 1,981 | $41.63K | May 2, 2024 | ESPP |
| Noyes Timothy Officer, Director | May 1, 2024 | 11,357 | $230.94K | May 1, 2024 | Employee Stock Purchase Plan |
| Benjamin T. Dake Officer | Apr 17, 2024 | 6,853 | $161.87K | Apr 17, 2024 | Options Grant |
| C. Gillies Hunter Officer | Apr 17, 2024 | 4,000 | $89.52K | Apr 17, 2024 | Stock Option Exercise |
| Noyes Timothy Officer, Director | Apr 16, 2024 | 10,000 | $246.97K | Apr 16, 2024 | Stock Option Exercise |